Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

DelMar Approved to Start China Phase II Trial of Brain Cancer Treatment

publication date: Jul 24, 2017
DelMar Pharma, a Canada-US biopharma, was approved to start a China Phase II trial of its lead candidate, VAL-083, which targets glioblastoma multiforme (GBM). The trial will test VAL-083 as a first-line GBM treatment in patients with newly diagnosed MGMT-unmethylated disease. Because the trial uses a patient's MGMT status as a biomarker, it required approval from China's Human Genetic Resources Administration. DelMar is partnering new China indications for VAL-083 with Guangxi Wuzhou Pharma, which already markets the drug in China for leukemia and lung cancer. More details....

Stock Symbol: (NSDQ: DMPI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital